Articles

The new division will provide system solutions and individual machines and components.

BHS-Sonthofen Combines Divisions to Create New Process Technology Division

The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.

BioMed X Launches Drug Delivery Research Project with Janssen

Sanofi will offer access to its infrastructure and expertise to help BioNTech produce over 125 million doses of its COVID-19 vaccine in Europe.

Sanofi to Help Manufacture and Supply BioNTech’s COVID-19 Vaccine

Emergent will use its CDMO services to manufacture drug product batches to support the increased supply of the therapeutic candidate in anticipation of a potential emergency use authorization in the first quarter of 2021.

Emergent and Humanigen Form CDMO Compact for COVID-19 Therapeutic Candidate 

Clinical material for a Theratechnologies product in development will be produced at PPS’ manufacturing facility in Lexington, KY.

Piramal Pharma Solutions to Provide Sterile Fill/Finish Support to Theratechnologies

The site, which is set to be operational in three years, will feature disposable technology and advanced technology filling lines to produce 90 million vials and 50 million pre-filled syringes a year. 

Civica to Launch Sterile Injectable Manufacturing Facility in Virginia

The two facilities consist of 260 and 130 permanent staff members respectively and produce liquid-filled hard capsules and softgels for the pharmaceutical market as well as other markets.

NextPharma to Acquire Two of Lonza’s European Facilities 

The companies have entered into an advance purchase agreement with COVAX to provide up to 40 million doses of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, to lower-middle-income countries.

Pfizer and BioNTech Enter into Agreement with COVAX for COVID-19 Vaccine Delivery 

Woodcock will serve as acting commissioner of FDA, taking over for Stephen Hahn, FDA’s previous acting commissioner. 

Janet Woodcock to Serve as Acting Commissioner of FDA

The company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, to focus on advancing its two SARS-CoV-2/COVID-19 therapeutic candidates, MK-4482 and MK-7110. 

News